Judette Marie Louis

Judette Marie Louis

Auto-generated profile, based on publicly available information

Judette Marie Louis

Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida Morsani College of Medicine, 2 Tampa General Circle, Tampa, FL 33606, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
FFFrancesca L. Md Facco
Francesca L. Md Facco
CPCorette B. DrPH Parker
Corette B. DrPH Parker
URUma M. Reddy
Uma M. Reddy
RSRobert M. Silver
Robert M. Silver
MKMatthew A. Koch
Matthew A. Koch
PZPhyllis C. Zee
Phyllis C. Zee
OBJECTIVE: To estimate whether sleep-disordered breathing during pregnancy is a risk factor for the development of hypertensive disorders of pregnancy and gestational diabetes mellitus (GDM). METHODS: In this prospective cohort study, nulliparous women underwent in-home sleep-disordered breathing assessments in early (6–15 weeks of gestation) and midpregnancy (22–31 weeks of gestation). Participants and health care providers were blinded to the sleep test results. An apnea–hypopnea index of 5 or greater was used to define sleep-disordered breathing. Exposure–response relationships were examined, grouping participants into four apnea–hypopnea index groups: 0, greater than 0 to less than 5, 5 to less than 15, and 15 or greater. The study was powered to test the primary hypothesis that sleep-disordered breathing occurring in pregnancy is associated with an increased incidence of preeclampsia. Secondary outcomes were rates of hypertensive disorders of pregnancy, defined as preeclampsia and antepartum gestational hypertension, and GDM. Crude and adjusted odds ratios and 95% confidence intervals (CIs) were calculated from univariate and multivariate logistic regression models. RESULTS: Three thousand seven hundred five women were enrolled. Apnea–hypopnea index data were available for 3,132 (84.5%) and 2,474 (66.8%) women in early and midpregnancy, respectively. The corresponding prevalence of sleep-disordered breathing was 3.6% and 8.3%. The prevalence of preeclampsia was 6.0%, hypertensive disorders of pregnancy 13.1%, and GDM 4.1%. In early and midpregnancy the adjusted odds ratios for preeclampsia when sleep-disordered breathing was present were 1.94 (95% CI 1.07–3.51) and 1.95 (95% CI 1.18–3.23), respectively; hypertensive disorders of pregnancy 1.46 (95% CI 0.91–2.32) and 1.73 (95% CI 1.19–2.52); and GDM 3.47 (95% CI 1.95–6.19) and 2.79 (95% CI 1.63–4.77). Increasing exposure–response relationships were observed between apnea–hypopnea index and both hypertensive disorders and GDM. CONCLUSION: There is an independent association between sleep-disordered breathing and preeclampsia, hypertensive disorders of pregnancy, and GDM.

1 May 2014 in SLEEP
Verified
Journal Article
Open access
PDF file
JLJudette M. Louis
Judette M. Louis
MMMulubrhan F. Mogos
Mulubrhan F. Mogos
Jason Lee SalemiJason Lee Salemi
Jason Lee Salemi
SRSusan Redline
Susan Redline
HSHamisu M. Salihu
Hamisu M. Salihu
Study Objectives:. A recent trend in increasing rates of severe maternal morbidity and mortality despite quality improvements has been noted. The goal

1 February 2022 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
JJJasmine D. Johnson
Jasmine D. Johnson
JLJudette M. Louis
Judette M. Louis

25 October 2019 in American Journal of Perinatology
Verified
Journal Article
Open access
PDF file
SBSean C. Blackwell
Sean C. Blackwell
CGCynthia Gyamfi-Bannerman
Cynthia Gyamfi-Bannerman
JBJoseph R. Biggio
Joseph R. Biggio
SCSuneet P. Chauhan
Suneet P. Chauhan
BHBrenna L. Hughes
Brenna L. Hughes
JKJulie Krop
Julie Krop
Background Women with a history of spontaneous preterm birth (SPTB) are at a significantly increased risk for recurrent preterm birth (PTB). To date, only one large U.S. clinical trial comparing 17-OHPC (17-α-hydroxyprogesterone caproate or “17P”) to placebo has been published, and this trial was stopped early due to a large treatment benefit. Objective This study aimed to assess whether 17-OHPC decreases recurrent PTB and neonatal morbidity in women with a prior SPTB in a singleton gestation. Study Design This was a double-blind, placebo-controlled international trial involving women with a previous singleton SPTB (clinicaltrials.gov: NCT 01004029). Women were enrolled at 93 clinical centers (41 in the United States and 52 outside the United States) between 160/7 to 206/7 weeks in a 2:1 ratio, to receive either weekly intramuscular (IM) injections of 250 mg of 17-OHPC or an inert oil placebo; treatment was continued until delivery or 36 weeks. Co-primary outcomes were PTB < 35 weeks and a neonatal morbidity composite index. The composite included any of the following: neonatal death, grade 3 or 4 intraventricular hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis, or proven sepsis. A planned sample size of 1,707 patients was estimated to provide 98% power to detect a 30% reduction in PTB < 35 weeks (30% to 21%) and 90% power to detect a 35% reduction in neonatal composite index (17%–11%) using a two-sided type-I error of 5%. Finally, this sample size would also provide 82.8% power to rule out a doubling in the risk of fetal/early infant death assuming a 4% fetal/early infant death rate. Analysis was performed according to the intention-to-treat principle. Results Baseline characteristics between the 1,130 women who received 17-OHPC and 578 women who received placebo were similar. Overall, 87% of enrolled women were Caucasian, 12% had >1 prior SPTB, 7% smoked cigarettes, and 89% were married/lived with partner. Prior to receiving study drug, 73% women had a transvaginal cervical length measurement performed and <2% had cervical shortening <25 mm. There were no significant differences in the frequency of PTB < 35 weeks (17-OHPC 11.0% vs. placebo 11.5%; relative risk = 0.95 [95% confidence interval (CI): 0.71–1.26]) or neonatal morbidity index (17-OHPC 5.6% vs. placebo 5.0%; relative risk = 1.12 [95% CI: 0.68–1.61]). There were also no differences in frequency of fetal/early infant death (17-OHPC 1.7% vs. placebo 1.9%; relative risk = 0.87 [95% CI: 0.4–1.81]. Maternal outcomes were also similar. In the subgroup of women enrolled in the United States (n = 391; 23% of all patients), although the rate of PTB < 35 weeks was higher than the overall study population, there were no statistically significant differences between groups (15.6% vs. 17.6%; relative risk = 0.88 [95% CI: 0.55, 1.40]. Conclusion In this study population, 17-OHPC did not decrease recurrent PTB and was not associated with increased fetal/early infant death. In women with a prior spontaneous preterm birth, weekly 17-OHPC compared with placebo did not reduce recurrent preterm birth or decrease neonatal morbidity. Date of registration: October 27, 2009. Date of initial participant enrollment: November 12, 2009. Clinical trials ID: NCT01004029. URL: https://clinicaltrials.gov/ct2/show/NCT01004029?term=17P+AMAG&rank=2.

1 November 2012 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
JLJudette Louis
Judette Louis
DADennis Auckley
Dennis Auckley
BMBranko Miladinovic
Branko Miladinovic
ASAnna Shepherd
Anna Shepherd
PMPatricia Mencin
Patricia Mencin
SRSusan Redline
Susan Redline
OBJECTIVE: To investigate the associations between obstructive sleep apnea (OSA) and maternal and neonatal morbidities in a cohort of obese gravid women. METHODS: Participants were enrolled in a prospective observational study designed to screen for OSA and describe the possible risk factors for and outcomes of OSA among obese (body mass index [BMI, calculated as weight (kg)/[height (m)]2] 30 or higher) pregnant women. Women underwent an overnight sleep study using a portable home monitor. Studies were manually scored by a central masked sleep reading center using American Academy of Sleep Medicine diagnostic criteria. An apnea hypopnea index of 5 or more was considered diagnostic of OSA. Perinatal outcomes were compared between women with and without OSA. RESULTS: Among 175 women, OSA prevalence was 15.4% (13 mild, 9 moderate, 5 severe). Compared with no OSA (apnea hypopnea index less than 5), the OSA group had a higher BMI (46.8±12.2 compared with 38.1±7.5; P=.002) and more chronic hypertension (55.6% compared with 32.4%, P=.02). Maternal complications included maternal death (n=1, amniotic fluid embolus [no OSA group]) and cardiac arrest (n=1, intraoperative at cesarean delivery [OSA group]). One previable birth and two stillbirths occurred in the no OSA group. Among live births, OSA was associated with more frequent cesarean delivery (65.4% compared with 32.8%; P=.003), preeclampsia (42.3% compared with 16.9%; P=.005), and neonatal intensive care unit admission (46.1% compared with 17.8%; P=.002). After controlling for BMI, maternal age, and diabetes, OSA (odds ratio [OR] 3.55, 95% confidence interval [CI] 1.1–11.3), previous preeclampsia (OR 2.79, 95% CI 1.09–7.19), and hypertension (OR 4.25, 95% CI 1.67–10.77) were associated with development of preeclampsia. CONCLUSION: Obstructive sleep apnea among obese pregnant women is associated with more frequent preeclampsia, neonatal intensive care unit admissions, and cesarean delivery. LEVEL OF EVIDENCE: II

1 October 2017 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
FFFrancesca L. Facco
Francesca L. Facco
WGWilliam A. Grobman
William A. Grobman
KRKathryn J. Reid
Kathryn J. Reid
CPCorette B. Parker
Corette B. Parker
SHShannon M. Hunter
Shannon M. Hunter
PZPhyllis C. Zee
Phyllis C. Zee